Christine Rossant

Supplementary Figure 8 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

Supplementary Figure 8: Spheroid end-of-study T=240h images

Supplementary Figure 9 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

Supplementary Figure 9: Neuroendocrine Differentiation Phenotypes in Prostate Cancer Liver Metastases

Supplementary Figure 10 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

Supplementary Figure 10: hPSMA expression on RP1 tumour cells is lost over time, even in tumours dosed with HSA only

Supplementary Figure 9 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

Supplementary Figure 9: Neuroendocrine Differentiation Phenotypes in Prostate Cancer Liver Metastases

Data from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

AbstractPurpose: CD137 is a T- and NK-cell costimulatory receptor involved in consolidating immunologic responses. The potent CD137 agonist urelumab has shown clinical promise as a cancer immunotherapeutic but development has been hampered by on-target off-tumor toxicities. A CD137 agonist targeted to the …

gb (code pays fourni par la source)

Supplemental Methods 1 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

Supplemental Methods

Supplementary Figure 3 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

Supplementary Figure 3: PK/TK dosing strategies

Supplementary Figure 8 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

Supplementary Figure 8: Spheroid end-of-study T=240h images

Supplementary Figure 11 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

Supplementary Figure 11: Vipivotide tetraxetan does not interfere with CB307 activity

Supplementary Figure 5 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

Supplementary Figure 5: CB307 binding to cell-presented targets

Supplementary Figure 5 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

Supplementary Figure 5: CB307 binding to cell-presented targets

Supplementary Figure 1 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

Supplementary Figure 1: Validation of CD137 immunohistochemistry